Introduction Acute severe ulcerative colitis (ASUC) is a life-threatening condition requiring urgent treatment. In patients who fail steroids, Infliximab is widely used as rescue therapy.
Introduction
Acute severe ulcerative colitis (ASUC) is a life-threatening condition requiring urgent treatment. In patients who fail steroids, Infliximab is widely used as rescue therapy. However, response is highly variable, and a significant proportion of patients still require colectomy despite treatment. One major limitation is the lack of individualized dosing strategies, as drug pharmacokinetics in ASUC are highly unpredictable due to inflammation, protein loss, and altered clearance.
Problem Statement
Standard infliximab dosing does not account for patient-specific pharmacokinetics, leading to suboptimal exposure and increased risk of colectomy in ASUC.
Summary
This multicenter study developed a pharmacokinetic-based model to personalize infliximab therapy in ASUC. The key finding was that infliximab exposure between weeks 2–4, adjusted for drug clearance (AUCw2–4/CL), strongly predicted colectomy risk within 90 days.
Patients with low exposure (log AUC/CL < 5.79) were identified as high risk for colectomy, with good predictive accuracy (≈85%). The model incorporated simple clinical parameters such as body weight, CRP, and drug levels to estimate individualized drug exposure.
This approach allows early identification of patients who may benefit from intensified dosing strategies, moving beyond fixed regimens toward precision therapy.
Clinically, this represents a paradigm shift—from “one-size-fits-all” rescue therapy to personalized infliximab optimization—aimed at maximizing colectomy-free survival in ASUC.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.